CN114191414A - Compound olaquindox digestive enzyme sustained-release pill - Google Patents
Compound olaquindox digestive enzyme sustained-release pill Download PDFInfo
- Publication number
- CN114191414A CN114191414A CN202111577914.0A CN202111577914A CN114191414A CN 114191414 A CN114191414 A CN 114191414A CN 202111577914 A CN202111577914 A CN 202111577914A CN 114191414 A CN114191414 A CN 114191414A
- Authority
- CN
- China
- Prior art keywords
- olaquindox
- compound
- digestive enzyme
- release pill
- sustained
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006187 pill Substances 0.000 title claims abstract description 37
- TURHTASYUMWZCC-UHFFFAOYSA-N Olaquindox [BAN:INN] Chemical compound C1=CC=C2N([O-])C(C)=C(C(=O)NCCO)[N+](=O)C2=C1 TURHTASYUMWZCC-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 229950010210 olaquindox Drugs 0.000 title claims abstract description 31
- 238000013268 sustained release Methods 0.000 title claims abstract description 18
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 18
- 102000038379 digestive enzymes Human genes 0.000 title claims abstract description 17
- 108091007734 digestive enzymes Proteins 0.000 title claims abstract description 17
- 150000001875 compounds Chemical class 0.000 title claims abstract description 16
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims abstract description 10
- 102000004190 Enzymes Human genes 0.000 claims abstract description 5
- 108090000790 Enzymes Proteins 0.000 claims abstract description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 5
- 229940075507 glyceryl monostearate Drugs 0.000 claims abstract description 5
- 239000008101 lactose Substances 0.000 claims abstract description 5
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims abstract description 5
- 239000000230 xanthan gum Substances 0.000 claims abstract description 5
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 5
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 5
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 5
- 238000002156 mixing Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 239000011248 coating agent Substances 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 238000005498 polishing Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 231100000572 poisoning Toxicity 0.000 abstract description 9
- 230000000607 poisoning effect Effects 0.000 abstract description 9
- 241000282887 Suidae Species 0.000 description 4
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a compound olaquindox digestive enzyme sustained-release pill, which comprises the following components in percentage by weight: 3-4 parts of olaquindox, 20-30 parts of temperature-resistant complex enzyme, 10-15 parts of lactose, 1-2 parts of xanthan gum and 6-10 parts of glyceryl monostearate. The compound olaquindox digestive enzyme sustained-release pill can effectively control the dosage and reduce the poisoning phenomenon.
Description
Technical Field
The invention relates to the technical field of feed additives, in particular to a compound olaquindox digestive enzyme sustained-release pill.
Background
China is the biggest pork producing country and consumer country in the world, and for a long time, in order to reduce the breeding risk and improve the breeding benefit, the use of the feed additive is a commonly adopted technical means in the breeding industry.
Olaquindox, and quinoxaline antibacterial drug, are mainly used for promoting growth of pigs with weight of less than 35kg, and also used for preventing and treating yellow scour, white scour of piglets and salmonella infection of pigs. However, olaquindox has serious adverse reactions in use, i.e., excessive poisoning, causing glomerular damage, and thus must be administered precisely.
In the traditional technology, the olaquindox premix is used in a mixed feeding mode, wherein 1-2 Kg (specification: 5%) of pigs or 100-200 g (specification: 50%) of pigs are fed per 1000Kg of feed. Although the olaquindox premix is specified in terms of specific usage amounts, in actual use, the following phenomena often occur:
1. in the mixed feeding, the medicine dosage is not uniform, so that the ingestion amount of each pig is large or small, the proper effect is easily caused or not caused by small dosage, and the glomerulus damage is caused by excessive poisoning.
2. When piglets are fed with the feed, although the ingested feed is positively correlated with the weight, for some individuals, the ingested feed is often influenced by factors such as individual cheating, diseases, tastes, environments, individual preferences and the like, and the phenomenon shown in the above 1 also occurs because the ingested feed is not positively correlated with the weight.
Disclosure of Invention
The invention aims to provide a compound olaquindox digestive enzyme sustained-release pill which can effectively control the dosage and reduce the poisoning phenomenon.
In order to realize the purpose, the invention provides a compound olaquindox digestive enzyme sustained-release pill which comprises the following components in parts by weight:
preferably, the components and the mixture ratio comprise:
preferably, the components and the mixture ratio comprise:
a preparation method of a compound olaquindox digestive enzyme sustained-release pill comprises the following specific steps:
s1, mixing olaquindox, temperature-resistant complex enzyme and lactose uniformly according to a certain proportion;
s2, uniformly mixing xanthan gum and glyceryl monostearate according to a certain proportion;
s3, adding the mixtures obtained in the step S1 and the step S2 together and uniformly mixing;
s4, adding pure water into the mixture obtained in the step S3, and making pills;
s5, drying the pills in a ventilated and cool place, and then transferring the pills to an oven to be dried at 45-50 ℃;
s6, transferring the dried pills to a coating pan, coating with wax, and polishing.
Therefore, the compound olaquindox digestive enzyme sustained-release pill is adopted, after the dosage of olaquindox is accurately calculated, various digestive enzymes and phagostimulants are compounded, the dosage form capable of being controlled at any time is prepared, so that accurate administration is realized, olaquindox is taken more accurately, the phenomena of poisoning, or failure and the like are powerfully reduced, the practicability is increased, the olaquindox in the pill is prepared into the sustained-release pill, and the effect of uniform absorption is achieved by controlling the release and the absorption of the olaquindox in the pill by intestinal tracts.
The sustained-release pill can powerfully control the dosage and reduce the poisoning phenomenon. In the former process of using the olaquindox premix, the poisoning phenomenon can reach about 1 percent, and the current basic level is no longer, unless manual use fails.
The technical solution of the present invention is further described in detail by the following examples.
Detailed Description
The technical solution of the present invention is further illustrated by the following examples.
Unless defined otherwise, technical or scientific terms used herein shall have the ordinary meaning as understood by one of ordinary skill in the art to which this invention belongs.
Example one
A compound olaquindox digestive enzyme sustained release pill, each pill weighs 0.4 g/granule, and total 10000 pills.
Wherein the composition comprises 300g of olaquindox, 2000g of temperature-resistant complex enzyme, 1000g of lactose, 100g of xanthan gum and 600g of glyceryl monostearate.
A preparation method of a compound olaquindox digestive enzyme sustained-release pill comprises the following specific steps:
s1, mixing olaquindox, temperature-resistant complex enzyme and lactose uniformly according to a certain proportion; wherein, the olaquindox amount is small, and a multiple dilution method is carried out to ensure the uniform mixing.
S2, uniformly mixing xanthan gum and glyceryl monostearate according to a certain proportion;
s3, adding the mixtures obtained in the step S1 and the step S2 together and uniformly mixing;
s4, adding pure water into the mixture obtained in the step S3, and making pills; the diameter of the pill is 8 mm.
S5, drying the pills in a ventilated and cool place, and then transferring the pills to an oven to be dried at 50 ℃;
s6, transferring the dried pills to a coating pan, coating with wax, and polishing.
Test of
(1) Test method
Selecting 2 weakest piglets from the piglets weaned in the same litter to be used as a test group, taking the remaining 10 piglets as a control group, feeding the control group in a common way without adding any additive, and adding the pill prepared in the first embodiment into the test group on the basis of the common feeding of the control group.
The test groups were given the feeding as follows and the piglets were weighed and recorded on a table. When the weight of the test group reaches 35kg, the test is stopped. Then, the test group and the control group were weighed, and the maximum weight and the average weight were measured. And (5) making comparison data.
The feeding method comprises the following steps:
one pellet (i.e., one pill) was administered for two days per piglet for the first week (post weaning, same below).
One piglet was given one day in the second week.
Three piglets were given every third week for two days.
Two piglets were given one day for each piglet in the fourth week.
The piglets were given 2.5 grains per day in the fifth week.
Every piglet in the sixth week, 3 piglets were given one day.
On day four of the fifth week, the experiment was complete and the data are summarized as follows:
through the comparison, the test group has a higher growth rate than the control group, is healthy and has no poisoning phenomenon.
Therefore, the compound olaquindox digestive enzyme sustained-release pill can effectively control the dosage and reduce the poisoning phenomenon.
Finally, it should be noted that: the above embodiments are only for illustrating the technical solutions of the present invention and not for limiting the same, and although the present invention is described in detail with reference to the preferred embodiments, those of ordinary skill in the art should understand that: modifications and equivalents may be made to the invention without departing from the spirit and scope of the invention.
Claims (4)
1. The compound olaquindox digestive enzyme sustained-release pill is characterized by comprising the following components in parts by weight:
2. the compound olaquindox digestive enzyme sustained-release pill according to claim 1, which is characterized by comprising the following components in parts by weight:
3. the compound olaquindox digestive enzyme sustained-release pill according to claim 1, which is characterized by comprising the following components in parts by weight:
4. a method for preparing the compound olaquindox digestive enzyme sustained-release pill as claimed in any one of claims 1 to 3, which is characterized by comprising the following steps:
s1, mixing olaquindox, temperature-resistant complex enzyme and lactose uniformly according to a certain proportion;
s2, uniformly mixing xanthan gum and glyceryl monostearate according to a certain proportion;
s3, adding the mixtures obtained in the step S1 and the step S2 together and uniformly mixing;
s4, adding pure water into the mixture obtained in the step S3, and making pills;
s5, drying the pills in a ventilated and cool place, and then transferring the pills to an oven to be dried at 45-50 ℃;
s6, transferring the dried pills to a coating pan, coating with wax, and polishing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111577914.0A CN114191414A (en) | 2021-12-22 | 2021-12-22 | Compound olaquindox digestive enzyme sustained-release pill |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111577914.0A CN114191414A (en) | 2021-12-22 | 2021-12-22 | Compound olaquindox digestive enzyme sustained-release pill |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114191414A true CN114191414A (en) | 2022-03-18 |
Family
ID=80655869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111577914.0A Pending CN114191414A (en) | 2021-12-22 | 2021-12-22 | Compound olaquindox digestive enzyme sustained-release pill |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114191414A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101011107A (en) * | 2007-01-24 | 2007-08-08 | 华中农业大学 | Pharmaceutical premixed agent for disease resistance and growth promotion and application thereof |
| CN102178115A (en) * | 2011-05-13 | 2011-09-14 | 成都华西希望农业科学技术研究所有限公司 | Compound feed for teaching piglets to eat foods other than breast milk |
| CN104814931A (en) * | 2015-04-14 | 2015-08-05 | 华南农业大学 | Olaquindox slow release particle and preparing method and application thereof |
| CN105147622A (en) * | 2015-09-28 | 2015-12-16 | 佛山市正典生物技术有限公司 | Homogeneous olaquindox granules and preparation method thereof |
| CN109965102A (en) * | 2019-02-27 | 2019-07-05 | 王允瑞 | A kind of cattle and sheep trace-element slow-release pill and preparation method thereof |
-
2021
- 2021-12-22 CN CN202111577914.0A patent/CN114191414A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101011107A (en) * | 2007-01-24 | 2007-08-08 | 华中农业大学 | Pharmaceutical premixed agent for disease resistance and growth promotion and application thereof |
| CN102178115A (en) * | 2011-05-13 | 2011-09-14 | 成都华西希望农业科学技术研究所有限公司 | Compound feed for teaching piglets to eat foods other than breast milk |
| CN104814931A (en) * | 2015-04-14 | 2015-08-05 | 华南农业大学 | Olaquindox slow release particle and preparing method and application thereof |
| CN105147622A (en) * | 2015-09-28 | 2015-12-16 | 佛山市正典生物技术有限公司 | Homogeneous olaquindox granules and preparation method thereof |
| CN109965102A (en) * | 2019-02-27 | 2019-07-05 | 王允瑞 | A kind of cattle and sheep trace-element slow-release pill and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 李步高等编著: "《猪饲料的配制》", 31 August 2005, 中国社会出版社 * |
| 胡荣峰主编: "《工业药剂学》", 31 August 2010, 中国中医药出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110200136A (en) | A kind of antibiotic-free, the weanling pig creep feed without homologous protein | |
| CN103875994B (en) | A kind of weanling pig atherosclerotic mixed feed and preparation method thereof | |
| CN102771683B (en) | Bacillus-subtilis-contained artificial milk extract premix for pigs and application of premix | |
| CN105104786A (en) | Pigling Chinese herbal medicine probiotics anti-diarrhoea complete formula feed and preparation method therefor | |
| CN103461686A (en) | Piglet special forage | |
| CN111109442A (en) | Compound feed for pregnant sows of Sichuan-Tibet black pigs and using method of compound feed | |
| CN110583890A (en) | Antibiotic-free semi-wet suckling pig feed | |
| CN105360577A (en) | Soluble premixed feed additives for improving poultry egg laying performance and preparation method thereof | |
| CN108576433A (en) | It is a kind of for the additive of agent of feed for nursing sow and agent of feed for nursing sow and preparation method thereof | |
| CN114191414A (en) | Compound olaquindox digestive enzyme sustained-release pill | |
| CN109964873B (en) | Feeding method for weaned piglets in creep transition stage | |
| CN112167440A (en) | Piglet artificial milk product replacing breast milk and processing method thereof | |
| CN111149945A (en) | Antibiotic-free feed additive, antibiotic-free crushing compound feed for chicks and preparation method and application of antibiotic-free crushing compound feed | |
| CN111387361A (en) | Antibiotic-free pellet-line nursing piglet feed and preparation method thereof | |
| CN111280342A (en) | Feed for meat geese in gosling stage and preparation method thereof | |
| CN1795742A (en) | Premix material of anti heat stress for milk cow and preparation method | |
| CN114617199A (en) | Creep feed for suckling pigs, creep compound feed for suckling pigs and preparation method of creep compound feed | |
| CN104839493A (en) | Sucking pig compound premix feed as well as preparation and use methods thereof | |
| CN111543556A (en) | Special compound feed for breeding monogastric herbivores and preparation method thereof | |
| CN110651910A (en) | Nutritional feed proportioning method suitable for weaned piglets | |
| CN112641002B (en) | Feed composition added with tiepin coating compound acidifier | |
| CN113397055A (en) | Piglet teaching and protecting feed and preparation method thereof | |
| CN116569991A (en) | Concentrated feed and complete ration for piglets and preparation method thereof | |
| CN1480059A (en) | Concentrated feed for pigs in all phases | |
| CN114601072A (en) | Feed composition for reducing heat stress of poultry and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wu Zhiguo Inventor after: Li Yanhong Inventor after: Zhao Yonggang Inventor after: Wang Aiqing Inventor after: Meng Xinying Inventor after: Su Hongjun Inventor after: Bi Huangcheng Inventor after: Dong Jinmei Inventor after: Wu Yonggang Inventor after: Li Zeran Inventor after: Shang Hongliang Inventor before: Wang Wenna Inventor before: Zhao Yonggang Inventor before: Wu Zhiguo Inventor before: Wang Aiqing Inventor before: Dong Jinmei Inventor before: Liu Shuzhen Inventor before: Li Guirong Inventor before: Li Zeran Inventor before: Shang Hongliang Inventor before: Li Yanhong |